Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Hypophosphataemia and hyperphosphataemia

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Severe hypophosphataemia with respiratory weakness, haemolysis, rhabdomyolysis, seizure, encephalopathy or cardiac dysfunction needs urgent monitored replacement through the local phosphate protocol. Marked hyperphosphataemia with symptomatic hypocalcaemia, tumour lysis, acute kidney injury or arrhythmia requires immediate oncology, renal and critical-care assessment; intravenous calcium is reserved for threatening calcium symptoms because it can increase calcium–phosphate precipitation.

Overview

Recognise acute phosphate-related respiratory and cellular dysfunction, prevent refeeding harm and manage renal phosphate excess without unsafe replacement.

Phosphate moves between cells, bone and extracellular fluid under PTH, vitamin D, FGF23, insulin and acid–base influence. Serum concentration therefore changes through redistribution as well as true balance. Low levels may be asymptomatic until severe, when ATP and oxygen-delivery failure produces weakness, ventilatory failure, rhabdomyolysis, haemolysis, platelet dysfunction, confusion and seizure.

High phosphate binds calcium and raises the calcium–phosphate product. Acute loads or cell lysis can cause symptomatic hypocalcaemia, tetany and soft-tissue deposition, while chronic CKD mineral and bone disorder contributes to secondary hyperparathyroidism and vascular calcification. A haemolysed sample may falsely raise phosphate and potassium together, so analytical context matters.

Both replacement and lowering can harm. Intravenous phosphate may cause abrupt hypocalcaemia, hypotension, metastatic calcification, renal injury and potassium or sodium load. Phosphate binders differ in calcium, metal and gastrointestinal risks and must match CKD stage, concurrent calcium and patient preference. Use renal, endocrine, nutrition, oncology and pharmacy expertise for severe or persistent disease.

Aetiology

01

Intracellular phosphate shift

Refeeding, insulin treatment and respiratory alkalosis move phosphate into cells, causing a rapid serum fall despite depleted or previously normal stores.

02

Reduced intake or increased loss

Malnutrition, alcohol dependence, malabsorption, renal wasting and phosphate-binding medicines can progressively deplete total-body phosphate, even before a severe serum fall appears.

03

Impaired renal excretion

Advanced kidney disease and low PTH effect allow phosphate to accumulate, often as part of chronic mineral and bone disorder.

04

Acute phosphate release or load

Tumour lysis, rhabdomyolysis, haemolysis and phosphate administration can raise serum phosphate rapidly and lower ionised calcium.

Pathophysiology

  1. 1
    Phosphate balance changes

    Redistribution, altered intake, kidney handling or cell breakdown changes the extracellular phosphate concentration and total-body availability.

  2. 2
    Deficiency impairs cellular energy

    Low phosphate limits ATP generation and red-cell oxygen delivery, weakening skeletal, respiratory and cardiac muscle and disrupting neurological function.

  3. 3
    Excess binds calcium

    High phosphate complexes with calcium, lowering ionised calcium and increasing deposition risk in vessels and soft tissues.

  4. 4
    Chronic feedback remodels bone

    Persistent renal phosphate retention promotes secondary hyperparathyroidism and abnormal bone turnover as part of kidney mineral-bone disease.

Clinical features and red flags

Respiratory muscle failureRed flag

New difficulty weaning ventilation, shallow breathing, weak cough or reduced vital capacity can reflect severe phosphate depletion and warrants urgent confirmation and replacement.

Cellular energy failureRed flag

Proximal weakness, rhabdomyolysis, haemolysis, impaired platelet function, confusion or seizure indicates systemic consequences beyond an incidental laboratory result.

Refeeding phenotypeRed flag

Oedema, tachycardia, weakness, delirium or respiratory deterioration after nutrition starts in a malnourished patient should prompt immediate phosphate, magnesium and potassium review.

Chronic bone disease

Bone pain, proximal myopathy, pseudofractures or fractures with persistently low phosphate suggests osteomalacia from vitamin D, FGF23, renal tubular or medicine-related disease.

Acute phosphate excessRed flag

Tetany, paraesthesia, QT prolongation or seizure after cell lysis, bowel preparation or phosphate administration may result from secondary hypocalcaemia and renal failure.

CKD mineral disorder

Persistently high phosphate with raised PTH, altered calcium and advanced kidney disease requires a longitudinal renal bone plan rather than isolated binder escalation.

Investigations

  1. 01
    Repeat phosphate with calcium and albuminFirst step
    Why
    Confirm direction and assess reciprocal calcium change and precipitation risk.
    Interpretation and limitations
    Use ionised calcium when acutely symptomatic; repeat a haemolysed or discordant sample rapidly, especially when potassium is also unexpectedly high.
  2. 02
    Magnesium, potassium, renal function and bicarbonate
    Why
    Identify refeeding, DKA recovery, kidney failure and constraints on replacement salt selection.
    Interpretation and limitations
    Companion low potassium and magnesium support intracellular shift or poor nutrition; renal failure limits phosphate excretion and magnifies replacement toxicity.
  3. 03
    Nutrition and treatment timeline
    Why
    Relate phosphate change to caloric delivery, insulin, ventilation, alcohol use and prior starvation.
    Interpretation and limitations
    A fall after carbohydrate or insulin in a high-risk person supports refeeding physiology and requires the whole nutrition rate and thiamine plan to be reviewed.
  4. 04
    Urinary phosphate handling
    Why
    Distinguish renal wasting from low intake, malabsorption or redistribution in persistent hypophosphataemia.
    Interpretation and limitations
    Use fractional tubular reabsorption or TmP/GFR with specialist timing; active replacement, fasting state and kidney impairment can make one urine sample misleading.

Differential diagnosis

01

Sampling haemolysis

Red-cell rupture can falsely raise phosphate and potassium together, so an unexpected high result should be confirmed promptly.

02

Refeeding syndrome

Recent nutritional restart after prolonged undernutrition with falling potassium and magnesium supports insulin-driven intracellular shift rather than isolated deficiency.

03

Respiratory alkalosis

Acute hyperventilation stimulates intracellular phosphate use and can cause a transient fall alongside alkalosis symptoms when supported by the history and examination.

04

Chronic kidney disease

Reduced filtration with high phosphate, altered calcium and rising PTH supports renal retention rather than an acute cellular release.

Management

01RefeedPrevent intracellular phosphate collapseFirst stepAn adult has prolonged minimal intake, major weight loss, alcohol dependence or low baseline phosphate, potassium or magnesium.+
  1. 1Apply NICE CG32 refeeding-risk criteria before nutrition, obtain baseline electrolytes and glucose and prescribe thiamine and multivitamin support through the local nutrition protocol.
  2. 2Start energy at the guideline rate appropriate to risk and replace potassium, phosphate and magnesium through planned oral, enteral or intravenous routes rather than waiting for symptoms.
  3. 3EscalationMonitor fluid balance, oedema, heart rate, respiratory status and electrolytes daily or more frequently, slowing nutritional progression and escalating when biochemical or organ dysfunction emerges.
02ReplaceTreat hypophosphataemia by consequencePhosphate is low with symptoms, severe concentration, inability to eat or an ongoing high-risk shift.+

Complications

01

Respiratory failure

Severe hypophosphataemia depletes muscle ATP, weakening the diaphragm and making spontaneous ventilation or liberation from mechanical ventilation difficult.

02

Rhabdomyolysis and haemolysis

Cellular energy failure damages skeletal muscle and red cells, releasing intracellular contents and worsening systemic illness.

03

Tetany and arrhythmia

Acute hyperphosphataemia lowers ionised calcium, producing paraesthesia, tetany, seizure and cardiac electrical instability in severe cases.

04

Vascular and soft-tissue calcification

Chronic phosphate excess in kidney disease promotes mineral deposition and contributes to cardiovascular and tissue morbidity.

Monitoring and follow-up

  • During severe intravenous replacement, repeat phosphate, calcium, potassium and renal function at the local protocol interval and before any additional prescription.
  • In high refeeding risk, monitor phosphate, magnesium, potassium, glucose, weight and fluid balance daily or more frequently while energy provision is advanced.
  • Assess respiratory muscle strength, ventilation, neurological state, CK and haemolysis when severe deficiency has produced organ dysfunction; a corrected number may precede clinical recovery.
  • After ferric carboxymaltose exposure, follow phosphate in patients receiving repeated high doses, long-term treatment or with risk factors, and reassess the iron product if hypophosphataemia persists.
  • For acute hyperphosphataemia, repeat calcium, potassium, urate and renal indices closely until cell lysis and rebound are controlled and dialysis need has passed.
  • In CKD, trend phosphate with calcium and PTH at renal-guideline intervals and review binder adherence, food timing, diet quality and dialysis adequacy together.

Special situations

Respiratory alkalosis shifts phosphate

Intracellular alkalinisation accelerates glycolysis and phosphate use, so severe hyperventilation can rapidly lower serum phosphate without a long history of poor intake.

DKA recovery unmasks depletion

Osmotic urinary losses create deficit, then insulin moves phosphate into cells; routine replacement is not automatic but severe symptoms require active treatment.

Refeeding is multisystem

Phosphate is the classic marker, but thiamine deficiency, sodium retention, low magnesium and low potassium jointly cause cardiac and neurological deterioration.

Iron can cause bone disease

Persistent renal phosphate wasting after ferric carboxymaltose may produce osteomalacia and fractures, a pattern easily mislabelled as anaemia-related fatigue.

Calcium treatment can precipitate

In acute phosphate excess, treat life-threatening hypocalcaemic manifestations but avoid chasing an asymptomatic calcium number and raising the mineral product unnecessarily.

Food additives matter in CKD

Inorganic phosphate additives are highly absorbable; specialist dietetic review can reduce them while preserving adequate protein and overall nutrition.

Common pitfalls

  1. 01

    Starting full calories in a severely malnourished patient and waiting for phosphate to fall before implementing thiamine and electrolyte prevention.

  2. 02

    Giving intravenous phosphate from memory without checking whether the preparation contains potassium or sodium and whether calcium is running through the same line.

  3. 03

    Treating a low serum phosphate but overlooking respiratory failure, rhabdomyolysis, haemolysis or the medicine causing ongoing renal wasting.

  4. 04

    Continuing repeated ferric carboxymaltose despite persistent hypophosphataemia, bone pain and fractures without reassessing the product and osteomalacia.

  5. 05

    Giving intravenous calcium routinely for asymptomatic hyperphosphataemic hypocalcaemia and increasing the risk of calcium–phosphate deposition.

  6. 06

    Restricting all protein in CKD to lower phosphate without renal-dietitian input, thereby worsening malnutrition and treatment outcomes.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Refeeding respiratory weakness

A severely malnourished adult becomes weak and breathless after rapid initiation of enteral feed. Phosphate, magnesium and potassium are all low. What is the best management principle?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG32 nutrition support recommendationsRefeeding-risk criteria, calorie initiation, thiamine and electrolyte replacement guidance.
  • BNF phosphate imbalance summaryUK oral and intravenous replacement and hyperphosphataemia treatment context.
  • NICE NG203 chronic kidney disease recommendationsAdvanced CKD diet, dialysis and phosphate-binder selection and monitoring.
  • MHRA ferric carboxymaltose phosphate warningRegulatory monitoring and product-reassessment advice for osteomalacia and fracture risk.
  • Phosphate Sandoz SmPCCurrent licensed oral product content and calcium, renal and soft-tissue calcification cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Key points

  • Phosphate is essential for ATP, 2,3-DPG, cell membranes, signalling and bone mineral, so severe deficiency can impair diaphragm, myocardium, brain, erythrocytes and leukocyte function.
  • A rapid intracellular shift follows refeeding, insulin treatment, respiratory alkalosis and recovery from DKA, and can produce profound symptoms despite a smaller preceding extracellular abnormality.
  • NICE identifies low phosphate, potassium or magnesium and prolonged minimal intake as major refeeding-risk features; prevention begins before calories are advanced.
  • Reduced absorption, vitamin D deficiency, diarrhoea, antacids and phosphate binders cause deficiency, while PTH or FGF23 excess and Fanconi syndromes cause renal wasting.
  • MHRA warns that repeated or high-dose ferric carboxymaltose can cause persistent hypophosphataemic osteomalacia and fractures, requiring risk-based phosphate monitoring and treatment review.
  • Use oral phosphate for suitable stable deficiency and reserve intravenous replacement for severe symptoms or very low concentrations, following a product-specific local chart with calcium, potassium and renal monitoring.
  • Hyperphosphataemia most commonly reflects acute or chronic kidney failure, tissue breakdown, tumour lysis, hypoparathyroidism or an exogenous phosphate load.
  • Chronic CKD management integrates dialysis adequacy, specialist diet and phosphate binders taken with food; it is not solved by reacting to one result or restricting protein indiscriminately.
  • 05
    PTH, vitamin D and alkaline phosphatase
    Why
    Investigate endocrine and bone causes of chronic low or high phosphate.
    Interpretation and limitations
    High PTH promotes phosphaturia, while high alkaline phosphatase with low phosphate supports osteomalacia; interpret calcitriol and FGF23 only through a specialist pathway.
  • 06
    Creatine kinase, full blood count and haemolysis markers
    Why
    Detect rhabdomyolysis, haemolysis or tumour lysis as a cause or complication.
    Interpretation and limitations
    High CK with low phosphate may reflect energy failure, whereas rapid high phosphate, potassium and urate with falling calcium suggests tumour lysis and urgent renal-oncology care.
  • 07
    Medicine and infusion review
    Why
    Find ferric carboxymaltose, antacids, binders, diuretics, tenofovir, chemotherapy or an iatrogenic phosphate load.
    Interpretation and limitations
    Document cumulative and repeat exposure; persistent low phosphate after ferric carboxymaltose should trigger product reassessment, not supplementation alone.
    • 1
    Assess respiratory, neurological, cardiac and muscle function with calcium, potassium, magnesium and renal status, and treat rhabdomyolysis or haemolysis supportively.
  • 2Use an approved oral preparation for stable disease; use the local intravenous phosphate chart for severe or symptomatic deficiency, choosing sodium or potassium content from the full electrolyte picture.
  • 3Repeat phosphate and calcium during treatment, stop for adverse change and investigate renal wasting, malabsorption, endocrine disease or medicine exposure when the deficit persists.
    • 03HighControl acute phosphate excessPhosphate rises rapidly with kidney failure, tumour lysis, tissue breakdown or exogenous administration.+
    1. 1Stop phosphate sources, use ABCDE and ECG, check ionised calcium, potassium, urate, creatinine and fluid state and activate the tumour-lysis or renal emergency pathway when relevant.
    2. 2Treat threatening symptomatic hypocalcaemia with calcium only under senior monitoring, because additional calcium can worsen calcium–phosphate deposition when symptoms are absent.
    3. 3Promote renal clearance with appropriate fluid when safe and seek urgent dialysis for severe persistent disease, kidney failure, dangerous potassium or symptomatic calcium disturbance.
    04CKDManage chronic hyperphosphataemiaRepeated results show high phosphate in stage 4 or 5 CKD or dialysis.+
    1. 1Review the trend with calcium, PTH, vitamin D, dialysis adequacy, adherence and diet, using a specialist renal dietitian to reduce highly bioavailable phosphate additives without causing malnutrition.
    2. 2Select and titrate phosphate binder through NICE NG203 and the local renal formulary, taking it with phosphate-containing food and considering calcium load, pill burden and gastrointestinal effects.
    3. 3Monitor the whole CKD mineral and bone disorder rather than targeting phosphate alone, involving the patient in trade-offs between diet, dialysis and medicines.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Replaces phosphate in stable deficiency when the gut is functional and rapid correction is unnecessary.

    Oral phosphate replacement

    Choose the current local licensed or approved preparation and divided dose according to phosphate concentration, symptoms, gastrointestinal tolerance, sodium and potassium content and renal function; confirm the specific product rather than converting by tablet count.

    Monitor calcium, potassium, sodium, creatinine and diarrhoea. Oral products vary in electrolyte load, are unsuitable in significant renal retention and can cause nephrocalcinosis or soft-tissue mineralisation if continued after the deficit resolves.

    Provides controlled replacement for severe symptomatic hypophosphataemia, respiratory failure or inability to absorb enteral therapy.

    Intravenous phosphate replacement

    Use only the organisation’s pharmacy-approved sodium- or potassium-phosphate product, dilution, line and infusion rate, with dose selected from the current measured level, symptoms, body size and renal function and reviewed before repetition.

    Rapid or excessive infusion can cause hypocalcaemia, hypotension, arrhythmia, acute kidney injury and calcium–phosphate precipitation. Check product potassium and sodium, infusion compatibility and access, and avoid simultaneous calcium-containing solutions.

    Reduces intestinal phosphate absorption as part of chronic CKD mineral and bone disorder management.

    Phosphate binders in advanced CKD

    Select agent and meal-linked dose through NICE NG203 and the specialist renal formulary after optimising diet and dialysis; titrate to serial phosphate and calcium rather than using one universal binder regimen.

    Calcium-based agents add calcium load, while non-calcium binders have distinct gastrointestinal, metal and interaction risks. Assess pill burden, adherence, nutrition and timing with food, and do not use chronic binders as sole treatment for acute tumour lysis.